Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05052619
Other study ID # Lac-infection
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date July 1, 2026

Study information

Verified date September 2021
Source Peking Union Medical College Hospital
Contact Yatong Li, MD
Phone 861069158547
Email yatongli@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intra-abdominal infection is one of the most serious complications after pancreatic resection. The preventive use of antibiotics intraoperatively could reduce the incidence rate of postoperative intra-abdominal infection. According to the previous retrospective study, changes of serum lactate level on postoperative day1 could predict the incidence rate of postoperative intra-abdominal infection. This prospective RCT is to further validate and promote the findings and conclusion.


Description:

Postoperative intra-abdominal infection is one of the most serious complications after pancreatic resection. Once diagnosed as postoperative intra-abdominal infection, the patient would not only suffer a lot, but also spend much more money and time in hospital. Moreover, subsequent sepsis and septic shock would imperil the patient's life. The preventive use of antibiotics intraoperatively is the key to prevent this complication, but the time, dosage, and choice of the antibiotics are worth discussing. According to the previous work, the investigators found the changes in serum lactate level on postoperative day (POD) 1 could predict postoperative intra-abdominal infection one week before it really happened. The cutoff level of lactate is 3.25mmol/L. Thus, the investigators recommend preventive use of advanced antibiotics for patients who have a peak serum lactate level of >3.250 mmol/L in 24h after pancreatic resection (doi: 10.1007/s00268-021-05987-8. PMID: 33604712). The investigators would verify the finding in this randomized controlled trial. Patients with peak lactate level >3.250 mmol/L in POD1 and met other inclusion criteria would be recruited and separated into "preventive use of advanced antibiotics group" (experimental group) and "routine group" (control group) randomly. Patients in experimental group would be treated with advanced antibiotics to avoid postoperative intra-abdominal infection. Patients in control group would be treated with routine method (antibiotics with lower levels). To compare the incidence rate of infection and other complications, as well as the payment and other index, the investigators would see if the patients in experimental group could have better prognosis after pancreatic surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 297
Est. completion date July 1, 2026
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. treatment by pancreatic resection, including pancreaticoduodenectomy, pancreatosplenectomy, total pancreatectomy, and other variant operations; 2. revival in the intensive care unit (ICU) with standard serum lactate elution treatments after surgery instead of the operation room or general ward; 3. availability of complete preoperative, intraoperative, and postoperative data; 4. the peak serum lactate level in 24 hours after surgery >3.250 mmol/L. Exclusion Criteria: 1. a history of surgical treatment of any upper abdominal lesions before the current hospital admission; 2. the minimum mean arterial pressure <65 mmHg during the operation; 3. without written informed consents for the perioperative situation and related studies.

Study Design


Intervention

Drug:
Preventive use of advanced antibiotics
Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
Other:
Routine
Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Li Y, Chen L, Xing C, Ding C, Zhang H, Wang S, Long Y, Guo J, Liao Q, Zhang T, Zhao Y, Dai M. Changes in Serum Lactate Level Predict Postoperative Intra-Abdominal Infection After Pancreatic Resection. World J Surg. 2021 Jun;45(6):1877-1886. doi: 10.1007/s — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence rate of postoperative intra-abdominal infection The incidence rate of postoperative intra-abdominal infection is expected to be lower in experimental group than control group in 30 days after surgery
Secondary The amount of white blood cell It is expected to be lower in experimental group than in control group postoperative days 1, 3, 5, 7, 14, 21, 28
Secondary The level of procalcitonin It is expected to be lower in experimental group than in control group postoperative days 1, 3, 5, 7, 14, 21, 28
Secondary The level of C-reactive protein It is expected to be lower in experimental group than in control group postoperative days 1, 3, 5, 7, 14, 21, 28
Secondary The level of interleukin It is expected to be lower in experimental group than in control group postoperative days 1, 3, 5, 7, 14, 21, 28
Secondary The level of tumor necrosis factor a It is expected to be lower in experimental group than in control group postoperative days 1, 3, 5, 7, 14, 21, 28
See also
  Status Clinical Trial Phase
Recruiting NCT05337566 - Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections N/A
Completed NCT02874872 - Building a Novel Antibiotic Stewardship Intervention for Nursing Homes N/A
Completed NCT03909698 - Antibiotic Dosing in Patients on Intermittent Hemodialysis
Not yet recruiting NCT06402292 - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute N/A
Recruiting NCT04669717 - Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Phase 4
Completed NCT04434300 - Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC) Phase 1
Completed NCT03464279 - Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections N/A
Completed NCT03131063 - Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation (PHARMECMO) N/A
Completed NCT03335137 - Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients N/A
Recruiting NCT05553743 - Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
Recruiting NCT05519761 - A Retrospective, Observational, Multicenter Study to Evaluate the Safety and Performance of POLYSITE® and SEESITE® Implantable Ports
Completed NCT02927743 - Effect of Evidence-based Reminders on Use of Antibiotics N/A
Not yet recruiting NCT03178292 - Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy N/A
Completed NCT02118402 - Iron and Prebiotics Fortification in Kenyan Infants N/A
Completed NCT00791505 - Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation Phase 3
Not yet recruiting NCT04966390 - Standardized Clinical Application of Antibacterial/Anitifungal Drugs
Recruiting NCT03014687 - Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Phase 4
Withdrawn NCT01463943 - Non-Inferiority Trial Comparing Eurofarma's Experimental Product Saccharomyces Boulardii Versus Floratil® in the Prevention of Antibiotic-Associated Diarrhea Phase 3
Completed NCT04493008 - Antibiotic Usage and Resistance; Knowledge and Practices Before and After Educational Sessions N/A
Recruiting NCT03361267 - Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection N/A